Tay-Sachs Disease Market Report and Forecast 2025-2034

The Tay-Sachs disease market size was valued at USD 2.30 Billion in 2024, driven by the rising advancements in stem cell therapies across the major markets. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2025-2034, with the values likely to rise to USD 3.97 Billion by 2034.

Tay-Sachs Disease: Introduction

Tay-Sachs disease is a rare genetic condition that affects a child's nerve cells in the brain and spinal cord. It is caused by the absence of an enzyme that helps break down fatty substances (also known as gangliosides). These substances build up to toxic levels and affect the impact the nerve cell functions. Early symptoms of the disease appear at about 3-6 months of age. The muscle development slows down and the child may experience seizures as well.

Tay-Sachs Disease Market Analysis

The Tay-Sachs disease market value is driven by the rising emphasis on mitigating the morbidities associated with the disease, which includes the development of new therapeutics and improving the existing system for improved results. AAV (adeno-associated virus) gene therapy is one of the latest therapies being investigated. It impacted the HexA activity which increased from the baseline and remained stable in patients.

In addition, there has been a significant development in other therapies as well, which includes enzyme replacement therapy, substrate reduction therapy, hematopoietic stem cell transplantation, gene therapies. The market growth is also driven by rising investments and grants for innovative treatment alternatives. The California Institute for Regenerative Medicine (CIRM) has invested a hefty sum of USD 4 million into UC Davis researchers to establish a stem cell gene therapy to treat the condition.

With a key focus on developing a genetic cure for GM2 gangliosidosis (including Tay-Sachs disease), several companies and organizations are collaborating to investigate and develop better therapies. In June 2023, New Hope Research Foundation and Forge Biologics partnered for the cGMP manufacturing to enhance the Foundation's NHR01, a novel gene therapy. Such collaborations are essential to meet the rising Tay-Sachs disease market demand and expected to boost market growth further in the coming years.

Tay-Sachs Disease Market Segmentation

Tay-Sachs Disease Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Type

• Anticonvulsants
• Antipsychotic Medications
• Others

Market Breakup by Type

• Infantile Tay - Sachs Disease
• Juvenile Tay-Sachs Disease
• Late-Onset Tay-Sachs Disease

Market Breakup by Treatment

• Medication
• Respiratory Care
• Physical Therapy

Market Breakup by Route of Administration

• Injectable
• Oral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Breakup by End User

• Hospitals
• Homecare

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan

Tay-Sachs Disease Market Overview

Early screening during pregnancy is a key method to prevent genetic disorders in children. As a result, pregnancy screenings are considered highly critical nowadays. In the historical period, the condition has been more prevalent in Central and Eastern European Jewish ancestry, therefore, Europe has led the Tay-Sachs disease market share. Having a robust healthcare, along with academic institutions, there have been significant enhancements to decrease the rising burden of the disease.

In North America, the United States is a major market with a heavy focus on disease detection at the pregnancy stage. Organizations such as JScreen have set up campaigns and have been actively encouraging people to undergo testing for genetic diseases. In the case of in-vitro fertilization, preimplantation genetic testing is widely applied.

Asia Pacific is expected to witness exponential Tay-Sachs disease market growth, with increasing medical and research advancements occurring in the region. Mergers and acquisitions between native and international corporations is further fostering the market growth in the region. In addition, foreign investments to put the easy availability of resources to use are also impacting the market positively.

Tay-Sachs Disease Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Recursion Pharmaceuticals, Inc.
• IntraBioInc
• Johnson & Johnson Services
• Axovant Sciences, Inc.
• Pfizer
• Sio Gene Therapies Ltd
• F. Hoffmann-La
• Roche Ltd
• Bayer AG
• Bausch Health
• Boehringer Ingelheim International GmbH

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.